Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering pri...
Chief Executive Officer Andrei Floroiu Resigns Chair Michael J. Finney, Ph.D. to Serve as Interim Chief Executive Officer SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in management. Effective immediately Andrei...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
On track to report topline data by the end of 2024 SOUTH SAN FRANCISCO, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed enrollment and dosing in the Phase 1 clinical trial evaluating Vaxart’s oral pill bivalent norovirus v...
Vaxart Inc. (VXRT) is expected to report $-0.18 for Q3 2023
2023-11-02 19:37:06 ET Vaxart, Inc. (NASDAQ:VXRT) Q3 2023 Earnings Conference Call November 2, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO Brant Biehn - SVP and Business Opera...
2023-11-02 16:09:43 ET More on Vaxart Vaxart Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart Financial information for Vaxart For further details see: Vaxart GAAP EPS of -$0.11 beats by $0...
Norovirus challenge study topline results indicate the potential of Vaxart’s oral pill vaccine candidate to reduce rates of norovirus infection, norovirus acute gastroenteritis and viral shedding Clinical proof of concept for the Company’s oral pill vaccine platform now es...
Trial evaluating the ability of oral vaccine tablets to induce breast milk antibodies and transfer of antibodies to young infants SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it has dosed the first subject in its Phase 1 clinic...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on ...
News, Short Squeeze, Breakout and More Instantly...
Palo Alto Networks, Inc. (NASDAQ:PANW) reported its third-quarter financial results after the bell Monday. Here's a look at the details from t...
Vaxart, Inc. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. Here's a look at the details. The Details...
Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine a...